IGC Pharma Inc.

11/25/2024 | Press release | Distributed by Public on 11/25/2024 07:58

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer’s Treatment